English

Dimension Therapeutics, Inc.

EDGAR

DMTX Quarterly report (10-Q) · filed 2017-11-06

11 filing records in this dataset, filed from 2015-09-14 to 2017-11-06. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

4.48 million USD

2017 Q3 · USD

Exact inputs and evidence

Revenue: 4480000 USD Source

Operating margin

-378.86%

2017 Q3 · %

Exact inputs and evidence

Operating Income: -16973000 USD Source
Revenue: 4480000 USD Source

Operating cash flow

-13.4 million USD

2017 Q3 · USD

Exact inputs and evidence

Operating Cash Flow: -42873000 USD Source
Operating Cash Flow: -29495000 USD Source

Free cash flow

-13.4 million USD

2017 Q3 · USD

Exact inputs and evidence

Operating Cash Flow: -42873000 USD Source
Operating Cash Flow: -29495000 USD Source
Capital Expenditure: 24000 USD Source
Capital Expenditure: 24000 USD Source

Cash and cash equivalents: 14.5 million USD 2017-09-30 Source
Exact value

14545000 USD
Long-term debt including current maturities: Not available
Shares outstanding: 25.2 million shares 2017-09-30 Source
Exact value

25209153 shares

Reported share-count change

0.66% · 166 thousand shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

25043506 shares · 2016-09-30· Source
25209153 shares · 2017-09-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

16.6 million USD

2016-10-01 – 2017-09-30

Exact inputs and evidence

Revenue: 4132000 USD · 2016-10-01 – 2016-12-31 Source
Revenue: 3618000 USD · 2017-01-01 – 2017-03-31 Source
Revenue: 4369000 USD · 2017-04-01 – 2017-06-30 Source
Revenue: 4480000 USD · 2017-07-01 – 2017-09-30 Source

Net income

-55.8 million USD

2016-10-01 – 2017-09-30

Exact inputs and evidence

Net income: -49001000 USD · 2016-01-01 – 2016-12-31 Source
Net income: -35976000 USD · 2016-01-01 – 2016-09-30 Source
Net income: -13492000 USD · 2017-01-01 – 2017-03-31 Source
Net income: -12309000 USD · 2017-04-01 – 2017-06-30 Source
Net income: -16947000 USD · 2017-07-01 – 2017-09-30 Source

Operating cash flow

-58.3 million USD

2016-10-01 – 2017-09-30

Exact inputs and evidence

Operating cash flow: -47644000 USD · 2016-01-01 – 2016-12-31 Source
Operating cash flow: -32252000 USD · 2016-01-01 – 2016-09-30 Source
Operating cash flow: -18222000 USD · 2017-01-01 – 2017-03-31 Source
Operating cash flow: -29495000 USD · 2017-01-01 – 2017-06-30 Source
Operating cash flow: -18222000 USD · 2017-01-01 – 2017-03-31 Source
Operating cash flow: -42873000 USD · 2017-01-01 – 2017-09-30 Source
Operating cash flow: -29495000 USD · 2017-01-01 – 2017-06-30 Source

Capital expenditure

304 thousand USD

2016-10-01 – 2017-09-30

Exact inputs and evidence

Capital expenditure: 6716000 USD · 2016-01-01 – 2016-12-31 Source
Capital expenditure: 6436000 USD · 2016-01-01 – 2016-09-30 Source
Capital expenditure: 24000 USD · 2017-01-01 – 2017-03-31 Source
Capital expenditure: 24000 USD · 2017-01-01 – 2017-06-30 Source
Capital expenditure: 24000 USD · 2017-01-01 – 2017-03-31 Source
Capital expenditure: 24000 USD · 2017-01-01 – 2017-09-30 Source
Capital expenditure: 24000 USD · 2017-01-01 – 2017-06-30 Source

Free cash flow

-58.6 million USD

2016-10-01 – 2017-09-30

Exact inputs and evidence

Operating cash flow: -47644000 USD · 2016-01-01 – 2016-12-31 Source
Operating cash flow: -32252000 USD · 2016-01-01 – 2016-09-30 Source
Operating cash flow: -18222000 USD · 2017-01-01 – 2017-03-31 Source
Operating cash flow: -29495000 USD · 2017-01-01 – 2017-06-30 Source
Operating cash flow: -18222000 USD · 2017-01-01 – 2017-03-31 Source
Operating cash flow: -42873000 USD · 2017-01-01 – 2017-09-30 Source
Operating cash flow: -29495000 USD · 2017-01-01 – 2017-06-30 Source
Capital expenditure: 6716000 USD · 2016-01-01 – 2016-12-31 Source
Capital expenditure: 6436000 USD · 2016-01-01 – 2016-09-30 Source
Capital expenditure: 24000 USD · 2017-01-01 – 2017-03-31 Source
Capital expenditure: 24000 USD · 2017-01-01 – 2017-06-30 Source
Capital expenditure: 24000 USD · 2017-01-01 – 2017-03-31 Source
Capital expenditure: 24000 USD · 2017-01-01 – 2017-09-30 Source
Capital expenditure: 24000 USD · 2017-01-01 – 2017-06-30 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2017-11-06.

Financial data available through: 2016-12-31.

Coverage by financial measure

Revenue: 3 of 11 periods available· newest 2016-12-31
Operating income: 3 of 11 periods available· newest 2016-12-31
Net income: 3 of 11 periods available· newest 2016-12-31
Operating cash flow: 3 of 11 periods available· newest 2016-12-31
Capital expenditure: 3 of 11 periods available· newest 2016-12-31
Total assets: 3 of 11 periods available· newest 2016-12-31
Total liabilities: 3 of 11 periods available· newest 2016-12-31
Current assets: 3 of 11 periods available· newest 2016-12-31
Current liabilities: 3 of 11 periods available· newest 2016-12-31
Cash and cash equivalents: 3 of 11 periods available· newest 2016-12-31
long term debt: No compatible figures in this window
Shares outstanding: 3 of 11 periods available· newest 2016-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
+48%

Prior period

USD 7.75 million

2015-01-01 – 2015-12-31
Current period

USD 11.47 million

2016-01-01 – 2016-12-31

Exact inputs and evidence

11471000 − 7750000 = 3721000 USD

7750000 USD · 2015-01-01 – 2015-12-31
Inspect prior input Prior source
11471000 USD · 2016-01-01 – 2016-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · Dimension Therapeutics, Inc. · 2016-12-31 Dimension Therapeutics, Inc. (edgar:1592288) Year-over-year change in Revenue: 3721000 USD Concept: fundies:Revenue Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T11:59:24Z Snapshot: be7662aa33a0b25cc49f5fd35fc563a955a1a643acea835d0878623145c2db35 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1592288?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 11471000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1592288/000156459017003781/dmtx-20161231.xml#147505 Filing: 000156459017003781 Input fundies:Revenue: 7750000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1592288/000156459017003781/dmtx-20161231.xml#147648 Filing: 000156459017003781
The citation records this snapshot. The page link may show a newer release later.
Net income
−USD 13.95 million

Prior period

−USD 35.06 million

2015-01-01 – 2015-12-31
Current period

−USD 49 million

2016-01-01 – 2016-12-31

Exact inputs and evidence

-49001000 − -35056000 = -13945000 USD

-35056000 USD · 2015-01-01 – 2015-12-31
Inspect prior input Prior source
-49001000 USD · 2016-01-01 – 2016-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · Dimension Therapeutics, Inc. · 2016-12-31 Dimension Therapeutics, Inc. (edgar:1592288) Year-over-year change in Net income: -13945000 USD Concept: fundies:NetIncome Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T11:59:24Z Snapshot: be7662aa33a0b25cc49f5fd35fc563a955a1a643acea835d0878623145c2db35 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1592288?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -49001000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1592288/000156459017003781/dmtx-20161231.xml#150623 Filing: 000156459017003781 Input fundies:NetIncome: -35056000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1592288/000156459017003781/dmtx-20161231.xml#150777 Filing: 000156459017003781
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 15.62 million

Prior period

−USD 32.03 million

2015-01-01 – 2015-12-31
Current period

−USD 47.64 million

2016-01-01 – 2016-12-31

Exact inputs and evidence

-47644000 − -32029000 = -15615000 USD

-32029000 USD · 2015-01-01 – 2015-12-31
Inspect prior input Prior source
-47644000 USD · 2016-01-01 – 2016-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · Dimension Therapeutics, Inc. · 2016-12-31 Dimension Therapeutics, Inc. (edgar:1592288) Year-over-year change in Operating cash flow: -15615000 USD Concept: fundies:OperatingCashFlow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T11:59:24Z Snapshot: be7662aa33a0b25cc49f5fd35fc563a955a1a643acea835d0878623145c2db35 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1592288?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -47644000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1592288/000156459017003781/dmtx-20161231.xml#181303 Filing: 000156459017003781 Input fundies:OperatingCashFlow: -32029000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1592288/000156459017003781/dmtx-20161231.xml#181555 Filing: 000156459017003781
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
+164.1%

Prior period

USD 2.54 million

2015-01-01 – 2015-12-31
Current period

USD 6.72 million

2016-01-01 – 2016-12-31

Exact inputs and evidence

6716000 − 2543000 = 4173000 USD

2543000 USD · 2015-01-01 – 2015-12-31
Inspect prior input Prior source
6716000 USD · 2016-01-01 – 2016-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · Dimension Therapeutics, Inc. · 2016-12-31 Dimension Therapeutics, Inc. (edgar:1592288) Year-over-year change in Capital expenditure: 4173000 USD Concept: fundies:CapitalExpenditure Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T11:59:24Z Snapshot: be7662aa33a0b25cc49f5fd35fc563a955a1a643acea835d0878623145c2db35 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1592288?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 6716000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1592288/000156459017003781/dmtx-20161231.xml#183306 Filing: 000156459017003781 Input fundies:CapitalExpenditure: 2543000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1592288/000156459017003781/dmtx-20161231.xml#183516 Filing: 000156459017003781
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2016 2016-01-01 – 2016-12-31

Revenue USD 11.47 million 100% of revenue
Operating costs Derived USD 60.52 million 528% of revenue
Operating income −USD 49.05 million −428% of revenue
Tax, interest and other Derived −USD 49,000 −0.4% of revenue
Net income −USD 49 million −427% of revenue

Cash

Operating cash flow −USD 47.64 million −415% of revenue
Capital expenditure USD 6.72 million 59% of revenue
Free cash flow Derived −USD 54.36 million −474% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2014 Operating loss: operating costs were 571% of revenue.
2015 Operating loss: operating costs were 551% of revenue.
2016 Operating loss: operating costs were 528% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2014 2014-01-01 – 2014-12-31	2750000	15701000 Derived	-12951000	17000 Derived	-12968000	7093000 Derived	Source 2014-01-01 – 2014-12-31: 2750000 USD Inspect Revenue Open source 2014-01-01 – 2014-12-31: -12951000 USD Inspect Operating Income Open source 2014-01-01 – 2014-12-31: -12968000 USD Inspect Net Income Open source 2014-01-01 – 2014-12-31: 8760000 USD Inspect Operating Cash Flow Open source 2014-01-01 – 2014-12-31: 1667000 USD Inspect Capital Expenditure Open source
2015 2015-01-01 – 2015-12-31	7750000	42715000 Derived	-34965000	91000 Derived	-35056000	-34572000 Derived	Source 2015-01-01 – 2015-12-31: 7750000 USD Inspect Revenue Open source 2015-01-01 – 2015-12-31: -34965000 USD Inspect Operating Income Open source 2015-01-01 – 2015-12-31: -35056000 USD Inspect Net Income Open source 2015-01-01 – 2015-12-31: -32029000 USD Inspect Operating Cash Flow Open source 2015-01-01 – 2015-12-31: 2543000 USD Inspect Capital Expenditure Open source
2016 2016-01-01 – 2016-12-31	11471000	60521000 Derived	-49050000	-49000 Derived	-49001000	-54360000 Derived	Source 2016-01-01 – 2016-12-31: 11471000 USD Inspect Revenue Open source 2016-01-01 – 2016-12-31: -49050000 USD Inspect Operating Income Open source 2016-01-01 – 2016-12-31: -49001000 USD Inspect Net Income Open source 2016-01-01 – 2016-12-31: -47644000 USD Inspect Operating Cash Flow Open source 2016-01-01 – 2016-12-31: 6716000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 11.5M 2016

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20142014-12-31	Revenue	2750000	Revenue: 2750000 Open source
20152015-12-31	Revenue	7750000	Revenue: 7750000 Open source
20162016-12-31	Revenue	11471000	Revenue: 11471000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

48% 2016

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20142014-12-31	Year over year	No prior comparable period	Revenue: 2750000 Open source
20152015-12-31	Year over year	181.8%	Revenue: 7750000 Open source Revenue: 2750000 Open source
20162016-12-31	Year over year	48%	Revenue: 11471000 Open source Revenue: 7750000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -427.6% 2016

Net margin -427.2% 2016

Free cash flow margin -473.9% 2016

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20142014-12-31	Operating margin	-470.9%	Operating Income: -12951000 Open source Revenue: 2750000 Open source
20152015-12-31	Operating margin	-451.2%	Operating Income: -34965000 Open source Revenue: 7750000 Open source
20162016-12-31	Operating margin	-427.6%	Operating Income: -49050000 Open source Revenue: 11471000 Open source
20142014-12-31	Net margin	-471.6%	Net Income: -12968000 Open source Revenue: 2750000 Open source
20152015-12-31	Net margin	-452.3%	Net Income: -35056000 Open source Revenue: 7750000 Open source
20162016-12-31	Net margin	-427.2%	Net Income: -49001000 Open source Revenue: 11471000 Open source
20142014-12-31	Free cash flow margin	257.9%	Revenue: 2750000 Open source Operating Cash Flow: 8760000 Open source Capital Expenditure: 1667000 Open source
20152015-12-31	Free cash flow margin	-446.1%	Revenue: 7750000 Open source Operating Cash Flow: -32029000 Open source Capital Expenditure: 2543000 Open source
20162016-12-31	Free cash flow margin	-473.9%	Revenue: 11471000 Open source Operating Cash Flow: -47644000 Open source Capital Expenditure: 6716000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -47.6M 2016

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20142014-12-31	Operating cash flow	8760000	Operating Cash Flow: 8760000 Open source
20152015-12-31	Operating cash flow	-32029000	Operating Cash Flow: -32029000 Open source
20162016-12-31	Operating cash flow	-47644000	Operating Cash Flow: -47644000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -54.4M 2016

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20142014-12-31	Free cash flow	7093000	Operating Cash Flow: 8760000 Open source Capital Expenditure: 1667000 Open source
20152015-12-31	Free cash flow	-34572000	Operating Cash Flow: -32029000 Open source Capital Expenditure: 2543000 Open source
20162016-12-31	Free cash flow	-54360000	Operating Cash Flow: -47644000 Open source Capital Expenditure: 6716000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

36.1% 2016

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20142014-12-31	Liabilities / assets	120.5%	Total Liabilities: 26671000 Open source Total Assets: 22133000 Open source
20152015-12-31	Liabilities / assets	20.8%	Total Liabilities: 27686000 Open source Total Assets: 133269000 Open source
20162016-12-31	Liabilities / assets	36.1%	Total Liabilities: 33924000 Open source Total Assets: 93865000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

4.13× 2016

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20142014-12-31	Current assets / current liabilities	2.54×	Current Assets: 20291000 Open source Current Liabilities: 7992000 Open source
20152015-12-31	Current assets / current liabilities	9.84×	Current Assets: 129930000 Open source Current Liabilities: 13201000 Open source
20162016-12-31	Current assets / current liabilities	4.13×	Current Assets: 85318000 Open source Current Liabilities: 20639000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2014 2014-01-01 – 2014-12-31	−USD 12.97 million Exact value Exact value: -12968000 USD 2014-01-01 – 2014-12-31: -12968000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Dimension Therapeutics, Inc. · 2014-12-31 Dimension Therapeutics, Inc. (edgar:1592288) Net Income: -12968000 USD Concept: fundies:NetIncome Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T11:59:24Z Snapshot: be7662aa33a0b25cc49f5fd35fc563a955a1a643acea835d0878623145c2db35 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1592288/explain?concept=fundies%3ANetIncome&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=USD&dimensions= Input fundies:NetIncome: -12968000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1592288/000156459017003781/dmtx-20161231.xml#150931 Filing: 000156459017003781 The citation records this snapshot. The page link may show a newer release later.	USD 8.76 million Exact value Exact value: 8760000 USD 2014-01-01 – 2014-12-31: 8760000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Dimension Therapeutics, Inc. · 2014-12-31 Dimension Therapeutics, Inc. (edgar:1592288) Operating Cash Flow: 8760000 USD Concept: fundies:OperatingCashFlow Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T11:59:24Z Snapshot: be7662aa33a0b25cc49f5fd35fc563a955a1a643acea835d0878623145c2db35 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1592288/explain?concept=fundies%3AOperatingCashFlow&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 8760000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1592288/000156459017003781/dmtx-20161231.xml#181807 Filing: 000156459017003781 The citation records this snapshot. The page link may show a newer release later.	USD 1.67 million Exact value Exact value: 1667000 USD 2014-01-01 – 2014-12-31: 1667000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Dimension Therapeutics, Inc. · 2014-12-31 Dimension Therapeutics, Inc. (edgar:1592288) Capital Expenditure: 1667000 USD Concept: fundies:CapitalExpenditure Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T11:59:24Z Snapshot: be7662aa33a0b25cc49f5fd35fc563a955a1a643acea835d0878623145c2db35 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1592288/explain?concept=fundies%3ACapitalExpenditure&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1667000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1592288/000156459017003781/dmtx-20161231.xml#183726 Filing: 000156459017003781 The citation records this snapshot. The page link may show a newer release later.	USD 7.09 million Calculation and evidence 8760000 − 1667000 USD Exact free cash flow: 7093000 USD 2014-01-01 – 2014-12-31: 8760000 USD · Inspect Operating Cash Flow · Source 2014-01-01 – 2014-12-31: 1667000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Dimension Therapeutics, Inc. · 2014-12-31 Dimension Therapeutics, Inc. (edgar:1592288) Free cash flow: 7093000 USD Concept: free-cash-flow Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T11:59:24Z Snapshot: be7662aa33a0b25cc49f5fd35fc563a955a1a643acea835d0878623145c2db35 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1592288?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 8760000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1592288/000156459017003781/dmtx-20161231.xml#181807 Filing: 000156459017003781 Input fundies:CapitalExpenditure: 1667000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1592288/000156459017003781/dmtx-20161231.xml#183726 Filing: 000156459017003781 The citation records this snapshot. The page link may show a newer release later.
2015 2015-01-01 – 2015-12-31	−USD 35.06 million Exact value Exact value: -35056000 USD 2015-01-01 – 2015-12-31: -35056000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Dimension Therapeutics, Inc. · 2015-12-31 Dimension Therapeutics, Inc. (edgar:1592288) Net Income: -35056000 USD Concept: fundies:NetIncome Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T11:59:24Z Snapshot: be7662aa33a0b25cc49f5fd35fc563a955a1a643acea835d0878623145c2db35 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1592288/explain?concept=fundies%3ANetIncome&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:NetIncome: -35056000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1592288/000156459017003781/dmtx-20161231.xml#150777 Filing: 000156459017003781 The citation records this snapshot. The page link may show a newer release later.	−USD 32.03 million Exact value Exact value: -32029000 USD 2015-01-01 – 2015-12-31: -32029000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Dimension Therapeutics, Inc. · 2015-12-31 Dimension Therapeutics, Inc. (edgar:1592288) Operating Cash Flow: -32029000 USD Concept: fundies:OperatingCashFlow Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T11:59:24Z Snapshot: be7662aa33a0b25cc49f5fd35fc563a955a1a643acea835d0878623145c2db35 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1592288/explain?concept=fundies%3AOperatingCashFlow&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -32029000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1592288/000156459017003781/dmtx-20161231.xml#181555 Filing: 000156459017003781 The citation records this snapshot. The page link may show a newer release later.	USD 2.54 million Exact value Exact value: 2543000 USD 2015-01-01 – 2015-12-31: 2543000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Dimension Therapeutics, Inc. · 2015-12-31 Dimension Therapeutics, Inc. (edgar:1592288) Capital Expenditure: 2543000 USD Concept: fundies:CapitalExpenditure Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T11:59:24Z Snapshot: be7662aa33a0b25cc49f5fd35fc563a955a1a643acea835d0878623145c2db35 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1592288/explain?concept=fundies%3ACapitalExpenditure&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 2543000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1592288/000156459017003781/dmtx-20161231.xml#183516 Filing: 000156459017003781 The citation records this snapshot. The page link may show a newer release later.	−USD 34.57 million Calculation and evidence -32029000 − 2543000 USD Exact free cash flow: -34572000 USD 2015-01-01 – 2015-12-31: -32029000 USD · Inspect Operating Cash Flow · Source 2015-01-01 – 2015-12-31: 2543000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Dimension Therapeutics, Inc. · 2015-12-31 Dimension Therapeutics, Inc. (edgar:1592288) Free cash flow: -34572000 USD Concept: free-cash-flow Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T11:59:24Z Snapshot: be7662aa33a0b25cc49f5fd35fc563a955a1a643acea835d0878623145c2db35 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1592288?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -32029000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1592288/000156459017003781/dmtx-20161231.xml#181555 Filing: 000156459017003781 Input fundies:CapitalExpenditure: 2543000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1592288/000156459017003781/dmtx-20161231.xml#183516 Filing: 000156459017003781 The citation records this snapshot. The page link may show a newer release later.
2016 2016-01-01 – 2016-12-31	−USD 49 million Exact value Exact value: -49001000 USD 2016-01-01 – 2016-12-31: -49001000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Dimension Therapeutics, Inc. · 2016-12-31 Dimension Therapeutics, Inc. (edgar:1592288) Net Income: -49001000 USD Concept: fundies:NetIncome Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T11:59:24Z Snapshot: be7662aa33a0b25cc49f5fd35fc563a955a1a643acea835d0878623145c2db35 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1592288/explain?concept=fundies%3ANetIncome&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:NetIncome: -49001000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1592288/000156459017003781/dmtx-20161231.xml#150623 Filing: 000156459017003781 The citation records this snapshot. The page link may show a newer release later.	−USD 47.64 million Exact value Exact value: -47644000 USD 2016-01-01 – 2016-12-31: -47644000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Dimension Therapeutics, Inc. · 2016-12-31 Dimension Therapeutics, Inc. (edgar:1592288) Operating Cash Flow: -47644000 USD Concept: fundies:OperatingCashFlow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T11:59:24Z Snapshot: be7662aa33a0b25cc49f5fd35fc563a955a1a643acea835d0878623145c2db35 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1592288/explain?concept=fundies%3AOperatingCashFlow&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -47644000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1592288/000156459017003781/dmtx-20161231.xml#181303 Filing: 000156459017003781 The citation records this snapshot. The page link may show a newer release later.	USD 6.72 million Exact value Exact value: 6716000 USD 2016-01-01 – 2016-12-31: 6716000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Dimension Therapeutics, Inc. · 2016-12-31 Dimension Therapeutics, Inc. (edgar:1592288) Capital Expenditure: 6716000 USD Concept: fundies:CapitalExpenditure Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T11:59:24Z Snapshot: be7662aa33a0b25cc49f5fd35fc563a955a1a643acea835d0878623145c2db35 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1592288/explain?concept=fundies%3ACapitalExpenditure&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 6716000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1592288/000156459017003781/dmtx-20161231.xml#183306 Filing: 000156459017003781 The citation records this snapshot. The page link may show a newer release later.	−USD 54.36 million Calculation and evidence -47644000 − 6716000 USD Exact free cash flow: -54360000 USD 2016-01-01 – 2016-12-31: -47644000 USD · Inspect Operating Cash Flow · Source 2016-01-01 – 2016-12-31: 6716000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Dimension Therapeutics, Inc. · 2016-12-31 Dimension Therapeutics, Inc. (edgar:1592288) Free cash flow: -54360000 USD Concept: free-cash-flow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T11:59:24Z Snapshot: be7662aa33a0b25cc49f5fd35fc563a955a1a643acea835d0878623145c2db35 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1592288?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -47644000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1592288/000156459017003781/dmtx-20161231.xml#181303 Filing: 000156459017003781 Input fundies:CapitalExpenditure: 6716000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1592288/000156459017003781/dmtx-20161231.xml#183306 Filing: 000156459017003781 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

11 filings · 644 latest values · 644 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001592288, 1592288, DMTX, edgar:1592288

Also known as Dimension Therapeutics, Inc.

Dimension Therapeutics, Inc.

Latest quarter

Revenue

Operating margin

Operating cash flow

Free cash flow

Reported share-count change

Trailing twelve months

Revenue

Net income

Operating cash flow

Capital expenditure

Free cash flow

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2016 2016-01-01 – 2016-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation